Adjuvant palbociclib in HR+/HER2-early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

被引：1
|
作者：
Gnant, Michael
Dueck, Amylou C.
Frantal, Sophie
Martin, Miguel
Burstein, Hal
Greil, Richard
Fox, Peter
Wolff, Antonio C.
Chan, Arlene
Winer, Eric
Singer, Christian
Miller, Kathy
Colleoni, Marco
Naughton, Michelle
Rubovszky, Gabor
Bliss, Judith
Mayer, Ingrid A.
Steger, Guenther G.
Nowecki, Zbigniew
Hahn, Olwen
Wolmark, Norman
Rugo, Hope
Pfeiler, Georg
Fohler, Hannes
Metzger, Otto
Schurmans, Celine
Theall, Kathy P.
Lu, Dongrui R.
Tenner, Kathleen
Fesl, Christian
DeMichele, Angela
Mayer, Erica L.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS1-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS1-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer
    Mayer, E. L.
    Gnant, M. I.
    DeMichele, A.
    Martin, M.
    Burstein, H.
    Prat, A.
    Rubovszky, G.
    Miller, K. D.
    Pfeiler, G.
    Winer, E. P.
    Zdenkowski, N.
    Anderson, D.
    Nowecki, Z.
    Loibl, S.
    Fohler, H.
    Metzger, O.
    Fumagalli, D.
    Theall, K. Puyana
    Fesl, C.
    Dueck, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1145 - S1145
  • [2] PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer
    Mayer, E.
    DeMichele, A.
    Dubsky, P.
    Barry, W.
    Metzger, O.
    Symmans, W. F.
    Burstein, H.
    Miller, K.
    Wolff, A.
    Rastogi, P.
    Loibl, S.
    von Minckwitz, G.
    Goulioti, T.
    Zardavas, D.
    Fesl, C.
    Koehler, M.
    Bartlett, C. Huang
    Chen, L.
    Piccart, M.
    Winer, E.
    Gnant, M.
    CANCER RESEARCH, 2016, 76
  • [3] Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2-early breast cancer
    Mayer, Erica L.
    Fesl, Christian
    Dueck, Amylou
    Gnant, Michael
    DeMichele, Angela
    CANCER RESEARCH, 2021, 81 (04)
  • [4] PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2-early breast cancer
    Mayer, Erica
    DeMichele, Angela
    Gnant, Michael
    Barry, William
    Pfeiler, Georg
    Metzger, Otto
    Burstein, Harold
    Miller, Kathy
    Rastogi, Priya
    Loibl, Sibylle
    Goulioti, Theodora
    Zardavas, Dimitrios
    Fesl, Christian
    Koehler, Maria
    Huang-Bartlett, Cynthia
    Huang, Xin
    Piccart, Martine
    Winer, Eric
    Wolff, Antonio
    CANCER RESEARCH, 2018, 78 (04)
  • [5] Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2-early breast cancer: Primary results from the phase III NATALEE trial.
    Slamon, Dennis J.
    Stroyakovskiy, Daniil
    Yardley, Denise A.
    Huang, Chiun-Sheng
    Fasching, Peter A.
    Crown, John
    Bardia, Aditya
    Chia, Stephen
    Im, Seock-Ah
    Martin, Miguel
    Loi, Sherene
    Xu, Binghe
    Hurvitz, Sara A.
    Barrios, Carlos
    Untch, Michael
    Moroose, Rebecca L.
    Visco, Fran
    Fresco, Rodrigo
    Taran, Tetiana
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [6] Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2-early breast cancer: Primary results from the phase III NATALEE trial.
    Stroyakovskiy, Daniil J.
    Yardley, Denise A.
    Huang, Chiun-Sheng
    Fasching, Peter A.
    Crown, John
    Bardia, Aditya
    Chia, Stephen
    Im, Seock-Ah
    Martin, Miguel
    Loi, Sherene
    Xu, Binghe
    Hurvitz, Sara A.
    Barrios, Carlos
    Untch, Michael
    Moroose, Rebecca L.
    Visco, Fran
    Fresco, Rodrigo
    Taran, Tetiana
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA500 - LBA500
  • [7] PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone HR1/HER2-early breast cancer
    Mayer, E. L.
    Demichele, A. M.
    Pfeiler, G.
    Barry, W.
    Metzger, O.
    Rastogi, P.
    Symmans, F.
    Burstein, H. J.
    Miller, K.
    Loibl, S.
    Schmatloch, S.
    Goulioti, T.
    Zardavas, D.
    Fesl, C.
    Koehler, M.
    Bartlett, C. Huang
    Huang, X.
    Piccart, M.
    Winer, E.
    Gnant, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer
    Slamon, Dennis J.
    Fasching, Peter A.
    Hurvitz, Sara
    Chia, Stephen
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Bardia, Aditya
    Im, Seock-Ah
    Yardley, Denise A.
    Untch, Michael
    Huang, Chiun-Sheng
    Stroyakovskiy, Daniil
    Xu, Binghe
    Moroose, Rebecca L.
    Loi, Sherene
    Visco, Frances
    Bee-Munteanu, Valerie
    Afenjar, Karen
    Fresco, Rodrigo
    Taran, Tetiana
    Chakravartty, Arunava
    Zarate, Juan Pablo
    Lteif, Agnes
    Hortobagyi, Gabriel N.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [9] Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2-early breast cancer
    Stover, Daniel
    Hlauschek, Dominik
    Mayer, Erica
    Symmans, W. Fraser
    Watson, Mark
    Barozzi, Iros
    Filipits, Martin
    Ballman, Karla
    Bellet-Ezquerra, Meritxell
    Balko, Justin
    Rubovszky, Gabor
    Zdenkowski, Nicholas
    Brufsky, Adam
    Steger, Guenther
    Isaacs, Claudine
    Loibl, Sibylle
    Henao, Fernando
    Regan, Meredith
    Liu, Yuan
    Fesl, Christian
    O'Brien, Patrick
    DeMichele, Angela
    Gnant, Michael
    Metzger, Otto
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Patient Preferences for HR+/HER2-Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment
    Harmer, Victoria
    Ammendolea, Cathy
    Ryan, Mandy
    Boyle, Frances
    Werutsky, Gustavo
    El Mouzain, Dina
    Marshall, Deborah A.
    Thomas, Caitlin
    Heidenreich, Sebastian
    Lu, Hui
    Krucien, Nicolas
    Payan, Juan Mora
    Aubel, Dawn
    Danyliv, Andriy
    Pathak, Purnima
    Harbeck, Nadia
    BREAST CARE, 2025, 20 (01)
12345